KORU Medical Systems Inc

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

KORU Medical Systems reports robust Q4 growth and eyes international expansion

KORU Medical Systems demonstrated strong financial performance in Q4 2022, with revenue growth and cash position exceeding expectations.
The company's strategic focus on novel therapies and international expansion presents growth opportunities, though margin improvement and market challenges remain.
With a clear Vision 26 strategy and positive revenue guidance for 2023, KORU is poised for continued growth and market leadership.

KORU Medical Systems excels in Q1 2023, poised for strategic growth

KORU Medical Systems delivered a robust performance in Q1 2023, showcasing growth across key business segments and strategic initiatives.
The company's focus on revenue targets, margin improvement, and operational efficiency positions it well for future success.
While challenges like managing cash burn and market dynamics exist, KORU's strengths in product leadership and financial management offer resilience.
Strategic opportunities in market expansion, innovation, and customer value creation provide a positive outlook for the company's growth trajectory.

KORU Medical Systems reports Q2 growth, projects improved margins

KORU Medical Systems demonstrated overall growth in Q2 2023, driven by strong performance in core businesses and improving gross margins. While facing challenges in Novel Therapies and a net cash operating loss, the company remains optimistic about future revenue growth and strategic initiatives.

KORU Medical Systems Inc reports Q3 revenue decline, focuses on margin expansion and Novel Therapies collaborations

KORU Medical Systems Inc faces revenue challenges but focuses on margin expansion, expense control, and strategic investments. The company aims for cash flow breakeven by Q4 2024, emphasizing Novel Therapies business and market growth assumptions.

KORU Medical Systems reports solid Q4 growth and outlines expansion plans for 2024

KORU Medical Systems' Q4 2023 performance reflects steady growth and strategic advancements in product development and market expansion. While facing challenges in production efficiency and European certification, the company is well-positioned to capitalize on opportunities in prefilled syringes and novel therapies for future growth.

KORU Medical Systems achieves record revenue and eyes global expansion

KORU Medical Systems delivered strong Q1 2024 results with record revenue and gross margin, alongside reduced cash burn.
The company reaffirmed guidance, secured new collaborations, and expanded internationally, while facing regulatory approval challenges.
Opportunities lie in FDA approvals, cash flow targets, and sustained U.S. core business growth through innovations and partnerships.

KORU Medical Systems excels in Q3, eyes growth opportunities

KORU Medical Systems delivered robust financial performance in Q3 2024, with raised revenue guidance and expectations of cash flow positivity in 2025.
The company's strategic focus on new product development and market expansion positions it well for sustained growth and profitability.
While facing challenges in maintaining growth momentum and operational efficiency, KORU's strong performance and outlook signal a promising future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022. Highlights: Year-over-year net sales growth of 15% to $6.2 million, marking the second

KORU Medical Systems Announces 2022 First Quarter Financial Results

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® a

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of EMPAVELI® (pegcetacoplan), Expands European Label for FreedomEdge®

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report first quarter 2022 financial results on Wednesday, May 4, 2022. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a co

KORU Medical Systems to Report First Quarter 2022 Financial Results on May 4, 2022

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Brian Case, a veteran medical technology R&D leader with over 20 years of experience, as the Company's new Chief Technology Officer. Mr. Case will lead product development and innovation as the Company defines

KORU Medical Systems Appoints Brian Case As Chief Technology Officer

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q4 2021 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 5.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Repro Med Systems, Inc. (KRMD) Reports Q4 Loss, Tops Revenue Estimates

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the fourth quarter and full year ended December 31, 2021. Highlights: Fourth quarter net revenues of $6.5 million, compared to

KORU Medical Systems Announces 2021 Q4 and Full Year Financial Results

Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Repro Med Systems, Inc. (KRMD) to Report a Decline in Earnings: What to Look Out for

CHESTER, N.Y.--(BUSINESS WIRE)--First paragraph, first sentence of release dated February 16, 2022, should read: Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022. [instead of Repro Med Systems, Inc. dba KO

CORRECTING and REPLACING KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2021. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results

KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2021

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols. “We are excited to an

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced it will host an investor day to provide an update to its strategic plan. KORU Medical Systems' management is scheduled to present on Thursday, December 9, 2021 at 10:00 AM EST. Interested parties can access the live and archived webc

KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q3 2021 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 10.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Repro Med Systems, Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2021. Recent Highlights: Achieved net revenue of $6.0 million, a 9% increase versus Q2 20

KORU Medical Systems Announces 2021 Third Quarter Financial Results

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion pump to deliver Hizentra® [immune globulin subcutaneous (human) 20% liquid] 20 mL p

KORU Medical Announces FDA Clearance for Delivery of Hizentra® Prefilled Syringes

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its participation in two upcoming conferences, Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 33rd Annual Piper Sandler Healthcare Conference. KORU Medical's management is scheduled to present

KORU Medical Systems to Participate in Two Upcoming Conferences

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing and commercialization of innovative and easy-to-use home infusion solutions, today announced its collaboration with Gilero, a medical device design and manufacturing company. Gilero offers unparalleled engineering and manufacturing solutions and has been a trusted partner for medical and

KORU Medical Announces Collaboration With Gilero to Accelerate Innovation

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of two new leaders who will be responsible for key elements of the Company's growth strategy: Rob Cannon as the Company's new Vice President of Sales, and Brian Hertzog as the Company's new Vice President of BioPharma

KORU Medical Expands Senior Team to Accelerate Growth Strategy

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2021 financial results on Wednesday, November 10, 2021. KORU Medical's management will host a conference

KORU Medical Systems to Report Third Quarter 2021 Financial Results on November 10, 2021

Earnings Preview: Repro Med Systems, Inc. (KRMD) Q3 Earnings Expected to Decline

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Chris Pazdan as the Company's new Vice President of Quality Assurance and Regulatory Affairs. Mr. Pazdan will be responsible for all quality assurance and regulatory affairs as the Company continues to build out a

KORU Medical Appoints Chris Pazdan as Vice President of Quality Assurance and Regulatory Affairs

KORU Medical Systems, Inc. (KRMD) CEO Linda Tharby on Q2 2021 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 10.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Repro Med Systems, Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Summary: Solid net revenue of $5.5 million; positive sequential qua

News for KORU Medical Systems Inc Stock (KRMD)